ZielBio, Inc., a US-based clinical-stage biotechnology company, announced on Tuesday that it has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead program, ZB131, intended to treat cholangiocarcinoma.
The product is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP).
The company said that during preclinical studies, the product showcased high specific binding to CSP and strong anti-cancer activity. The company is conducting a Phase 1/2 trial to study the safety, tolerability, and efficacy of the product in patients with solid tumours, including cholangiocarcinoma, pancreatic, and ovarian cancers.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML